EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSMPUG00000001700
Gene Symbol: GRIK2
2 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSMPUG00000014760
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSMPUG00000005636
Gene Symbol: GRIK4
2 Cross references
260 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSMPUG00000007345
Gene Symbol: GRIK5
2 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSMPUG00000011831
Gene Symbol: GRM2
2 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSMPUG00000018303
Gene Symbol: GRM3
2 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSMPUG00000003090
Gene Symbol: GRM4
2 Cross references
272 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSMPUG00000010375
Gene Symbol: GRM5
1 Cross references
272 Possible Orthologues:

Glutaminase

Ensembl ID : ENSMPUG00000012452
Gene Symbol: GLS
2 Cross references
302 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSMPUG00000007543
Gene Symbol: GSK3A
1 Cross references
260 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSMPUG00000008359
Gene Symbol: GSK3B
2 Cross references
241 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSMPUG00000005166
Gene Symbol: GHRHR
4 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).